Search: onr:"swepub:oai:lup.lub.lu.se:3c089537-923a-439e-8310-82e4a292229e" >
Cytarabine dose int...
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
-
- Abé, Christoph (author)
- Karolinska Institute,Quantify Research AB
-
- Keto, Jaana (author)
- Jazz Pharmaceuticals, Denmark
-
- Lilja, Mathias (author)
- Quantify Research AB
-
show more...
-
- Konradsen, Mie (author)
- Quantify Research AB
-
- Mesterton, Johan (author)
- Karolinska Institute,Quantify Research AB
-
- Höglund, Martin (author)
- Uppsala University
-
- Lazarevic, Vladimir (author)
- Lund University,Lunds universitet,Leukemi, genetik, epidemiologi,Forskargrupper vid Lunds universitet,Leukemia, Genetics, Epidemiology,Lund University Research Groups,Skåne University Hospital
-
- Lehmann, Sören (author)
- Uppsala University,Karolinska Institute,Uppsala University Hospital
-
- Juliusson, Gunnar (author)
- Lund University,Lunds universitet,Leukemi, genetik, epidemiologi,Forskargrupper vid Lunds universitet,Leukemia, Genetics, Epidemiology,Lund University Research Groups,Skåne University Hospital
-
show less...
-
(creator_code:org_t)
- 2024
- 2024
- English.
-
In: Leukemia and Lymphoma. - 1042-8194 .- 1029-2403.
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Since 1980’s, the established/standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). We compared the 7 + 3 regimen in older secondary/high-risk AML patientsfrom a clinical trial with a matched population from the Swedish AML Registrytreated withan increased cytarabine dose in induction and consolidation as recommended in the Swedish National Guidelines since 2005. After successfulpropensity score matching, 104 patients per group were included. The primary outcome was overall survival (OS), and standard dosed patients had a median OS of 6.4 versus 10.7 months with increased dose intensity (hazard ratio:0.69, p = 0.012), with 5-year OS of 8.7% and 18.1%, andremission rates of 36% and 60%, respectively (p < 0.001). Median OS after allogeneic hematopoietic cell transplantation (in 27.9% per group) was 10.4 and 20.7 months, respectively. We conclude that the more intensive cytarabine schedule seems to provide improved outcomes inthe investigated AML patient group.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Conventional 7 + 3 regimen
- external control arm
- hematopoietic cell transplantation
- overall survival
- real-world data
- standard of care
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database